Compare ARK Innovation ETF (ARKK) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Innovation ETF vs Summit Therapeutics Inc — how do they compare? ARK Innovation ETF trades at $81.5, while Summit Therapeutics Inc trades at $15.1 (market cap $12.06B). The key difference: ARK Innovation ETF is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| ARKK | SMMT | |
|---|---|---|
52-Week High | $92.50 | $26.98 |
52-Week Low | $63.52 | $12.55 |
Market Cap | — | $12.06B |
Sector | — | Health |
Enterprise Value | — | $11.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKK trades at $81.22, up 0.94% today, with a bullish technical signal from moving averages but a neutral stance from oscillators. The ETF's concentrated portfolio in disruptive innovation faces mixed sentiment, with recent news highlighting both buying activity in AI stocks like CoreWeave and concerns over high fees and underperformance versus the S&P 500. Key resistance is at $82, with support at $79.
Outlook remains volatile; ARKK offers exposure to high-growth themes like AI and space technology but carries significant concentration risk and fee drag. Investment opportunity hinges on successful bets in unprofitable ventures, while risks include dependency on Tesla and SpaceX performance and broader market shifts away from speculative growth.
Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.
Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Innovation ETF
The fund will invest under normal circumstances primarily (at least 65% of its assets) in domestic and foreign equity securities of companies that are relevant to the fund’s investment theme of disruptive innovation. Its investments in foreign equity securities will be in both developed and emerging markets. The fund may invest in foreign securities listed on foreign exchanges as well as American Depositary Receipts (ADRs) and Global Depositary Receipts (GDRs). The fund is non-diversified.
Read more on ARKK →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
